$151 Million is the total value of Lynx1 Capital Management LP's 18 reported holdings in Q3 2023. The portfolio turnover from Q2 2023 to Q3 2023 was 100.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| CMPS | Exit | COMPASS PATHWAYS PLCsponsored ads | $0 | – | -20,114 | -100.0% | -0.11% | – |
| PHVS | Exit | PHARVARIS N V | $0 | – | -21,225 | -100.0% | -0.21% | – |
| ATHA | Exit | ATHIRA PHARMA INC | $0 | – | -193,573 | -100.0% | -0.37% | – |
| Exit | STRUCTURE THERAPEUTICS INCsponsored ads | $0 | – | -23,000 | -100.0% | -0.63% | – | |
| CGEM | Exit | CULLINAN ONCOLOGY INC | $0 | – | -115,063 | -100.0% | -0.81% | – |
| NLTX | Exit | NEOLEUKIN THERAPEUTICS INC | $0 | – | -3,094,554 | -100.0% | -1.68% | – |
| Exit | PARDES BIOSCIENCES INC | $0 | – | -3,902,434 | -100.0% | -4.63% | – |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2023-11-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| MERUS N V | 8 | Q3 2023 | 21.9% |
| ALPINE IMMUNE SCIENCES INC | 8 | Q3 2023 | 20.2% |
| CYMABAY THERAPEUTICS INC | 8 | Q3 2023 | 10.0% |
| THESEUS PHARMACEUTICALS INC | 8 | Q3 2023 | 5.6% |
| PIERIS PHARMACEUTICALS INC | 8 | Q3 2023 | 5.8% |
| KINNATE BIOPHARMA INC | 7 | Q3 2023 | 18.0% |
| PARDES BIOSCIENCES INC | 7 | Q2 2023 | 11.0% |
| PASSAGE BIO INC | 7 | Q3 2023 | 4.0% |
| BELLUS HEALTH INC NEW | 6 | Q1 2023 | 22.7% |
| CABALETTA BIO INC | 4 | Q3 2023 | 22.6% |
View Lynx1 Capital Management LP's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-05-15 |
| 4 | 2024-04-23 |
| SC 13G | 2024-04-01 |
| SC 13G | 2024-03-29 |
| SC 13G | 2024-02-16 |
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
View Lynx1 Capital Management LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.